Acute Myeloid Leukemia Clinical Trial Landscape

Active Phase 3 AML Programs (2026)

Active Phase 2 Programs: Menin Inhibitors

Active Phase 2 Programs: VEN+AZA Combinations and FLT3

Platform / Master Protocol Trials

What Is Acute Myeloid Leukemia?

Acute myeloid leukemia (AML) is a hematologic malignancy arising from clonal expansion of immature myeloid progenitor cells (blasts) in the bone marrow. The disease is defined by ≥20% blasts in the marrow, though certain cytogenetic abnormalities qualify as AML at any blast percentage. AML is the most common acute leukemia in adults, with a median age at diagnosis of ~68 years and an annual incidence of approximately 20,000 new cases in the United States.

Unlike CLL or CML, AML is rapidly fatal without treatment, median survival without therapy is weeks to months. The disease is molecularly heterogeneous, driven by diverse somatic mutations that broadly fall into categories: (1) signaling mutations (FLT3-ITD/TKD, KIT, RAS), drive proliferation; (2) epigenetic mutations (IDH1/2, TET2, DNMT3A, EZH2), block differentiation; (3) transcription factor fusions (KMT2A/MLL rearrangements, RUNX1-RUNX1T1, CBF), disrupt normal myeloid development; (4) cohesin/spliceosome/TP53 mutations, associated with high-risk or therapy-related AML.

The Menin Inhibitor Revolution

The most important mechanistic advance in AML in the last decade, possibly since the discovery of FLT3 inhibitors, is the menin inhibitor class. The key insight came from understanding how KMT2A fusions (MLL rearrangements) and mutant NPM1 maintain leukemic stem cell identity: both oncogenic programs require the menin-KMT2A protein complex to activate HOX gene transcription programs that keep cells undifferentiated.

Revumenib (Revuforj, Syndax/Sanofi) received FDA accelerated approval in November 2024 based on the AUGMENT-101 trial: 23% complete remission rate in heavily pretreated R/R KMT2A-r or NPM1-mutant AML. Approximately half of complete responders achieved undetectable MRD, enabling allogeneic transplant in some patients. Side effects include differentiation syndrome (similar to ATRA/ATO in APL) and QTc prolongation, both manageable with monitoring and dose modification.

Ziftomenib (KO-539, Kura Oncology) and bleximenib (JNJ-75276617, Janssen) are second-generation menin inhibitors in development, potentially with improved potency or selectivity. Bleximenib's Phase 3 trial (NCT06852222) is the critical next step, testing whether adding a menin inhibitor to VEN+AZA can establish a new standard of care for 40% of newly diagnosed AML patients.

IDH Inhibitors: The Earlier Generation

IDH (isocitrate dehydrogenase) mutations. IDH1 (present in ~8% of AML) and IDH2 (~12%), were the first epigenetic targets to yield approved drugs. IDH1/2-mutant enzymes produce the oncometabolite 2-hydroxyglutarate, which inhibits TET2 and other α-ketoglutarate–dependent dioxygenases, causing epigenetic dysregulation and differentiation block. Enasidenib (Idhifa, Bristol-Myers Squibb/Servier) targets IDH2; ivosidenib (Tibsovo, Servier) targets IDH1; olutasidenib (Rezlidhia, Forma/Novo Nordisk) is a second-generation IDH1 inhibitor. All three are approved in R/R AML; ivosidenib is also approved in newly diagnosed IDH1-mutant AML with azacitidine. Like menin inhibitors, IDH inhibitors induce differentiation of leukemic blasts, a mechanism called "differentiation therapy" that is distinct from traditional cytotoxic chemotherapy.

Key Questions Driving AML Trials in 2026

• Can VEN+AZA + menin inhibitor become a standard of care? The Janssen Phase 3 bleximenib trial is the pivotal test, if positive, it would affect ~40% of newly diagnosed AML patients.
• Who benefits from intensive chemotherapy vs. VEN+AZA? In fit younger patients, is 7+3 induction still superior, or can VEN+AZA-based combinations match intensive therapy with less toxicity?
• Can MRD guide treatment decisions in AML? MRD-based discontinuation or escalation approaches (BLAST MRD, gilteritinib maintenance trials) are testing whether real-time molecular monitoring can personalize post-remission therapy.
• What to do after VEN+AZA failure? As VEN+AZA becomes standard frontline therapy, the relapsed/refractory post-VEN+AZA setting is growing, menin inhibitors, IDH inhibitors, and novel agents are the emerging options.
• How to incorporate transplant for intermediate/high-risk patients? Multiple trials are testing whether adding novel agents (venetoclax, FLT3 inhibitors, menin inhibitors) to transplant conditioning or maintenance improves outcomes.

Frequently asked questions

Related Disease Pages

• Chronic Lymphocytic Leukemia (CLL) Clinical Trials: BTK inhibitors, sonrotoclax, venetoclax
• Leukemia Clinical Trials Overview: all leukemia subtypes
• Mantle Cell Lymphoma Clinical Trials: BTK degraders, BCL-2 inhibitors
• DLBCL Clinical Trials: CAR-T, bispecific antibodies
• Non-Hodgkin Lymphoma Overview